Alliances and Partnerships
Each relationship is unique, but generally the alliances include a joint steering committee that meets regularly, dedicated project managers on both sides, a contractual framework that results in no contract or budget negotiations for 3-5 years and substantial financial and resource commitments.
Additionally, some of the alliances may contain a risk-sharing component.
Abbvie
The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will join forces to find new ways to unleash the immune system’s potential to fight cancer.
Adimab, LLC
Collaboration to develop therapeutic antibodies.
View press release (Dec. 8,2015)
Astellas Pharma
Agreement to develop a new treatment for patients with acute myeloid leukemia.
View press release (April 3, 2015)
AstraZeneca
Studies with AstraZeneca target gynecologic cancers.
View press release (Jan. 30, 2015)
Axxam
MD Anderson’s Neurodegeneration Consortium collaborates with Axxam to identify and develop novel small molecule modulators of an undisclosed G-protein coupled receptor linked to Alzheimer’s disease.
View press release (Dec. 4, 2015)
Boehringer Ingelheim
MD Anderson and Boehringer Ingelheim team up to develop innovative medicines for pancreatic ductal adenocarcinoma.
View press release (Dec. 2, 2015)
Cellectis
MD Anderson and Cellectis announce CAR T-cell preclinical and clinical strategic alliance.
View press release (Sept. 3, 2015)
Codiak
Strategic collaboration to develop exosomes as a new therapeutic and diagnostic modality.
View press release (Nov. 17, 2015)
CytoMx
Cytomx and MD Anderson collaborate to research PRoCAR-NK cell therapies.
View press release,(Nov. 5, 2015)
Enumeral
Scientists from Enumeral and MD Anderson will collaborate on the discovery and development of novel monoclonal antibodies against specified targets in immuno-oncology.
View press release (Jan. 1, 2016)
Foundation Medicine
MD Anderson, Foundation Medicine team up to improve targeted therapies in metastatic disease.
View press release (Aug. 14, 2014)
Helsinn Healthcare SA
Strategic alliance in cancer supportive and palliative care.
View press release (April 26, 2016)
Intrexon/ZIOPHARM
Alliance to develop non-viral adoptive cellular cancer immunotherapies.
View press release (Jan. 13, 2015)
Janssen
MD Anderson Announces Collaboration with Johnson & Johnson Innovation on cancer immunotherapy (Janssen is an affiliate of Johnson & Johnson Innovation)
View press release (Jan. 21, 2014)
Janssen, Johnson & Johnson Innovation
MD Anderson Announces Collaboration with Johnson & Johnson Innovation on cancer immunotherapy. (Janssen is an affiliate of Johnson & Johnson Innovation)
View press release (Jan. 21, 2014)
Karus
Strategic pre-clinical and clinical collaboration that will include development of KA2237 and KA2507.
View press release (Dec. 10, 2015)
Kymab
Kymab and MD Anderson announce a strategic cancer drug discovery and development alliance.
View press release (Jan. 7, 2016)
Merck
MD Anderson announces that they have entered into a strategic collaboration with Merck to evaluate Merck’s anti-PD-1 therapy in combination with other treatments.
View press release (August 13, 2015)
Moleculin
Collaboration to translate small molecules with anti cancer activity into clinical therapies.
NanoString Technologies
MD Anderson and NanoString Technologies Announce Multi-Year Collaboration
View press release (April 1, 2015)
Nektar
Nektar Therapeutics and MD Anderson announce a research collaboration that includes a Phase 1/2 clinical study to evaluate NKTR-214.
View press release (June 2, 2015)
Oncoceutics
Oncoceutics and MD Anderson team up on novel drug.
View press release (Jan. 5, 2015)
Oncora Medical, Inc.
View press release (April 2017)
OncoResponse
OncoResponse and MD Anderson collaborate to identify therapeutic antibodies against novel targets from immuno-oncology treated patients.
View press release (Oct. 6, 2015)
Polaris Pharmaceuticals
(April 2018)
Tesaro
Collaboration to discover and develop small molecule product candidates against undisclosed immuno-oncology targets.
View press release (March 29, 2016)
X-Chem
Strategic collaboration to identify and develop novel cancer agents to multiple targets.
View press release (Jan. 6, 2016)